GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3SBio Inc (OTCPK:TRSBF) » Definitions » Ending Cash Position

3SBio (TRSBF) Ending Cash Position : $366 Mil (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is 3SBio Ending Cash Position?

3SBio's Ending Cash Position for the quarter that ended in Dec. 2023 was $366 Mil.

3SBio's quarterly Ending Cash Position declined from Dec. 2022 ($309 Mil) to Jun. 2023 ($289 Mil) but then increased from Jun. 2023 ($289 Mil) to Dec. 2023 ($366 Mil).

3SBio's annual Ending Cash Position declined from Dec. 2021 ($450 Mil) to Dec. 2022 ($309 Mil) but then increased from Dec. 2022 ($309 Mil) to Dec. 2023 ($366 Mil).

3SBio Ending Cash Position Historical Data

The historical data trend for 3SBio's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3SBio Ending Cash Position Chart

3SBio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 296.97 472.66 450.30 308.64 365.70

3SBio Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 450.30 437.59 308.64 289.26 365.70

3SBio Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

3SBio's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=301.358+64.341
=366

3SBio's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=290.121+75.578
=366

3SBio Ending Cash Position Related Terms

Thank you for viewing the detailed overview of 3SBio's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

3SBio (TRSBF) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3SBio Inc (OTCPK:TRSBF) » Definitions » Ending Cash Position
Comparable Companies
HKSE:06826 HKSE:06990 HKSE:02162 HKSE:09688 HKSE:09969 HKSE:01541 HKSE:06660 HKSE:09966 HKSE:01952 HKSE:02315 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
01530:Hong Kong 83B:Germany
Address
No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone, Shenyang, CHN, 110027
Website
https://www.3sbio.com
3SBio Inc, or 3SBio, is one of the largest and most established biotech drugmakers in China. In 2021, it reported revenue of CNY 6.3 billion. Approximately 90% of its revenue is derived from four core drugs: TPIAO (rhTPO), Yisaipu (biosimilar of etanercept, a TNF-alpha inhibitor), rhEPO, and Mandi (minoxidil). With the exception of minoxidil, an over-the-counter drug, the others are all older generation biologics. Most of the pipeline candidates are "me-too" drugs and in general are still at an early stage.

3SBio (TRSBF) Headlines

No Headlines